Nice, June 22 -- New research has found immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint inhibitors.

The study was led by Assistant Professor Pilar Martin, Head of the Regulatory Molecules of Inflammation Lab at the Spanish National Centre for Cardiovascular Research (CNIC) and group leader at CIBER-CV.

She explained, "Immune checkpoint inhibitors have revolutionised cancer treatment, but they can also damage the hearts of some patients. In this study, we monitored how levels of immune cells, which are known to be involved in the development of heart diseases, change after treatment.

"We were surprised to see an earl...